Leap therapeutics1/10/2024 Following the merger, Leap will have 9,392,868 shares of common stock outstanding.įor more information about Leap Therapeutics, visit or our public filings with the SEC that are available via EDGAR at or via. In connection with the closing of the merger, HealthCare Ventures invested $10 million into Leap Therapeutics at a price of $9.90 per share. Notable drug approvals from these companies include Campath, Lemtrada, Entyvio, Velcade, Vyndaqel, and Zolinza. Onsi have worked together for over 20 years and developed dozens of biotechnology companies, public and private, including Adheron Therapeutics (acquired by Roche), Aton Pharmaceuticals (acquired by Merck), FoldRx (acquired by Pfizer), LeukoSite (acquired by Millennium Pharmaceuticals), Proteostasis Therapeutics, and Tensha Therapeutics (acquired by Roche). Augustine Lawlor, Chief Operating Officer.Mirabelli, Ph.D., Chairman of the Board and Chief Executive Officer Cholangiocarcinoma Foundation Annual Conference, February 2017, Presentation of DKN-01 biomarker and clinical data in biliary tract cancer.American Society for Clinical Oncology Gastrointestinal Symposium, January 2017, Poster presentation of DKN-01 biomarker and clinical data in gastroesophageal cancers.Society for Immunotherapy in Cancer, November 2016, Oral presentation of TRX518 biomarker clinical data.Recent and Upcoming Clinical Data Presentations ![]() TRX518 is being studied in two ongoing repeat-dose clinical trials in patients with advanced solid tumor malignancies. ![]() In clinical studies, a single-dose of TRX518 is associated with a reduction in immunosuppressive cells known as T regulatory cells. TRX518 is engineered to enhance immune responses to cancer. TRX518: TRX518 is a humanized monoclonal antibody with agonist activity targeting glucocorticord-inducible TNF-superfamily receptor (GITR). DKN-01 has demonstrated single agent activity in non-small cell lung cancer patients. DKN-01 is being studied in clinical trials in patients with esophageal, gastric, and biliary tract cancers. Recent literature suggests DKK1 has an important role in tumor cell signaling and in mediating an immuno-suppressive tumor microenvironment. DKK1 expression has been associated with poor prognosis in multiple cancers. Leap Therapeutics is conducting clinical studies with two best-in-class therapeutics.ĭKN-01: DKN-01 is a humanized monoclonal antibody that binds to and blocks the action of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. We expect that Leap’s novel assets will create significant value for shareholders as the programs progress.” “We are now well positioned to advance the development of our two clinical-stage monoclonal antibodies. Mirabelli, Ph.D., Chairman and Chief Executive Officer. “Leap Therapeutics has achieved a milestone in our growth by becoming a public company,” commented Christopher K. Leap will be listed on The Nasdaq Global Market under the symbol “LPTX” and expects to begin trading on Tuesday, January 24, 2017. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced the completion of its merger with Macrocure Ltd (Nasdaq:MCUR), with Macrocure becoming a wholly-owned subsidiary of Leap. 23, 2017 (GLOBE NEWSWIRE) - Leap Therapeutics, Inc.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |